Literature DB >> 17911062

Thymectomy for myasthenia gravis: prognostic factors in 70 patients.

Manucher Aghajanzadeh1, Hossein Khoshrang, Ali Mohammadzadeh, Seyed A Roudbari, Amir R Ghayeghran.   

Abstract

Thymectomy has become increasingly accepted as an efficacious procedure for myasthenia gravis, with high rates of complete clinical remission. Predictors of the response to thymectomy for myasthenia gravis vary in the literature. We retrospectively reviewed the clinical records of 70 patients (63% female; mean age, 38 years) diagnosed with myasthenia gravis from August 1993 to August 2004, to determine the factors predicting outcome. Complications occurred in 20%, but there was no hospital mortality. Complete clinical remission was obtained postoperatively in 47%. Our results indicate that patients with less than 1 year's duration of disease have a better prognosis, and Osserman stages I, IIa, and IIb are also associated with higher clinical remission rates. Female patients have a better prognosis than males, and the younger the patient the better the outcome. Thymectomy is indicated for myasthenia gravis as early as possible in the course of the disease.

Entities:  

Mesh:

Year:  2007        PMID: 17911062     DOI: 10.1177/021849230701500503

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  3 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Incidence of thymoma in myasthenia gravis: a systematic review.

Authors:  Zhi-Feng Mao; Xue-An Mo; Chao Qin; Yong-Rong Lai; Maree L Hackett
Journal:  J Clin Neurol       Date:  2012-09-27       Impact factor: 3.077

3.  Clinical outcome of thymectomy in myasthenia gravis patients: A report from Iran.

Authors:  Benyamin Seyfari; Farzad Fatehi; Abolfazl Shojaiefard; Mehdi Jafari; Ali Ghorbani-Abdehgah; Shirzad Nasiri; Aidin Yaghoobi-Notash; Behnam Molavi; Amir Hossein Latif; Reza Eslamian; Ali Mir; Ahmadreza Soroush
Journal:  Iran J Neurol       Date:  2018-01-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.